The influence of NK alloreactivity on matched unrelated donor and HLA identical sibling haematopoietic stem cell transplantation

Current Opinion in Immunology

Volumn 21, Issue 5, 2009, Pages 531-537

  Witt, Campbell S ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOIMMUNITY; CLINICAL PROTOCOL; DONOR; DONOR SELECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; LYMPHOCYTE COUNT; NATURAL KILLER CELL; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; RETROSPECTIVE STUDY; REVIEW; SIBLING; T LYMPHOCYTE;

DONOR SELECTION; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; KILLER CELLS, NATURAL; SIBLINGS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 70349790197     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2009.08.004     Document Type: Review

References (36)

1. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., Posati S., Rogaia D., Frassoni F., Aversa F., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 (2002) 2097-2100. Essential reading for anyone wishing to understand NK alloreactivity and why it is relevant to stem cell transplantation.
2. Ferrara J.L., Guillen F.J., van Dijken P.J., Marion A., Murphy G.F., and Burakoff S.J. Evidence that large granular lymphocytes of donor origin mediate acute graft-versus-host disease. Transplantation 47 (1989) 50-54
3. Rhoades J.L., Cibull M.L., Thompson J.S., Henslee-Downey P.J., Jennings C.D., Sinn H.P., Brown S.A., Eichhorn T.R., Cave M.L., and Jezek D.A. Role of natural killer cells in the pathogenesis of human acute graft-versus-host disease. Transplantation 56 (1993) 113-120
4. Ghayur T., Seemayer T.A., Kongshavn P.A., Gartner J.G., and Lapp W.S. Graft-versus-host reactions in the beige mouse. An investigation of the role of host and donor natural killer cells in the pathogenesis of graft-versus-host disease. Transplantation 44 (1987) 261-267
5. Morishima Y., Yabe T., Matsuo K., Kashiwase K., Inoko H., Saji H., Yamamoto K., Maruya E., Akatsuka Y., Onizuka M., et al. Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor. Biol Blood Marrow Transplant 13 (2007) 315-328. A well-designed study with large numbers of patients receiving transplants under relatively uniform transplant protocol. Very convincingly demonstrates effects of ligand incompatibility and separates effects of ligand incompatibility from HLA-C allele mismatching.
6. Farag S.S., Bacigalupo A., Eapen M., Hurley C., Dupont B., Caligiuri M.A., Boudreau C., Nelson G., Oudshoorn M., van Rood J., et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant 12 (2006) 876-884. A large study providing convincing evidence that ligand incompatibility results in poorer outcome relative to HLA matched transplants. Sufficiently powered to demonstrate that ligand mismatching did not produce a more deleterious effect than HLA-C and HLA-B allele mismatching.
7. Hsu K.C., Gooley T., Malkki M., Pinto-Agnello C., Dupont B., Bignon J.D., Bornhauser M., Christiansen F., Gratwohl A., Morishima Y., et al. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 12 (2006) 828-836. A large study that failed to find any effect of ligand incompatibility but did find evidence that the missing ligand model results in decreased relapse. This study demonstrates that even well-powered studies will not necessarily detect effects of ligand incompatibility.
8. Yabe T., Matsuo K., Hirayasu K., Kashiwase K., Kawamura-Ishii S., Tanaka H., Ogawa A., Takanashi M., Satake M., Nakajima K., et al. Donor killer immunoglobulin-like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-C-KIR ligand-mismatched T cell-replete unrelated bone marrow transplantation. Biol Blood Marrow Transplant 14 (2008) 75-87. A large well-designed study that demonstrates the potential for NK alloreactivity to have opposite effects under different transplant protocols.
9. Cooley S., Trachtenberg E., Bergemann T.L., Saeteurn K., Klein J., Le C.T., Marsh S.G., Guethlein L.A., Parham P., Miller J.S., and Weisdorf D.J. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 113 (2009) 726-732. A large well-powered study demonstrating the influence of donor KIR repertoire.
10. Hsu K.C., Pinto-Agnello C., Gooley T., Malkki M., Dupont B., and Petersdorf E.W. Hematopoietic stem cell transplantation: killer immunoglobulin-like receptor component. Tissue Antigens 69 Suppl 1 (2007) 42-45
11. Giebel S., Nowak I., Dziaczkowska J., Czerw T., Wojnar J., Krawczyk-Kulis M., Holowiecki J., Holowiecka-Goral A., Markiewicz M., Kopera M., et al. Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus host disease and affect survival after allogeneic hematopoietic stem cell transplantation. Eur J Haematol (2009) ePub ahead of print. One of the few studies to evaluate more than one method of analysing the effects of KIR repertoire on outcome.
12. Giebel S., Dziaczkowska J., Wojnar J., Krawczyk-Kulis M., Markiewicz M., Kruzel T., Wylezol I., Nowak K., Jagoda K., and Holowiecki J. The impact of immunosuppressive therapy on an early quantitative NK cell reconstitution after allogeneic haematopoietic cell transplantation. Ann Transplant 10 (2005) 29-33
13. Muller C., Schernthaner G., Kovarik J., Kalinowska W., and Zielinski C.C. Natural killer cell activity and antibody-dependent cellular cytotoxicity in patients under various immunosuppressive regimens. Clin Immunol Immunopathol 44 (1987) 12-19
14. Wang H., Grzywacz B., Sukovich D., McCullar V., Cao Q., Lee A.B., Blazar B.R., Cornfield D.N., Miller J.S., and Verneris M.R. The unexpected effect of cyclosporin A on CD56+. Blood 110 (2007) 1530-1539
15. Davies S.M., Ruggieri L., DeFor T., Wagner J.E., Weisdorf D.J., Miller J.S., Velardi A., and Blazar B.R. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 100 (2002) 3825-3827
16. De Santis D., Bishara A., Witt C.S., Nagler A., Brautbar C., Slavin S., and Christiansen F.T. HLA natural killer cell HLA-C epitopes and killer cell immunoglobulin-like receptors both influence outcome of mismatched unrelated donor bone marrow transplants. Tissue Antigens 65 (2005) 519-528
17. Bornhauser M., Schwerdtfeger R., Martin H., Frank K.H., Theuser C., Ehninger G., Locatelli F., Velardi A., and Giebel S. Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood 103 (2004) 2860-2861
18. Schaffer M., Malmberg K.J., Ringden O., Ljunggren H.G., and Remberger M. Increased infection-related mortality in KIR-ligand-mismatched unrelated allogeneic hematopoietic stem-cell transplantation. Transplantation 78 (2004) 1081-1085
19. Kroger N., Binder T., Zabelina T., Wolschke C., Schieder H., Renges H., Ayuk F., Dahlke J., Eiermann T., and Zander A. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation 82 (2006) 1024-1030
20. Lowe E.J., Turner V., Handgretinger R., Horwitz E.M., Benaim E., Hale G.A., Woodard P., and Leung W. T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation. Br J Haematol 123 (2003) 323-326
21. Miller J.S., Cooley S., Parham P., Farag S.S., Verneris M.R., McQueen K.L., Guethlein L.A., Trachtenberg E.A., Haagenson M., Horowitz M.M., et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 109 (2007) 5058-5061
22. Hsu K.C., Keever-Taylor C.A., Wilton A., Pinto C., Heller G., Arkun K., O'Reilly R.J., Horowitz M.M., and Dupont B. Improved outcome in HLA-identical sibling hematopoietic stem cell transplantation for acute myelogenous leukemia (AML) predicted by KIR and HLA genotypes. Blood 105 (2005) 4878-4884
23. Sun J.Y., Gaidulis L., Dagis A., Palmer J., Rodriguez R., Miller M.M., Forman S.J., and Senitzer D. Killer Ig-like receptor (KIR) compatibility plays a role in the prevalence of acute GVHD in unrelated hematopoietic cell transplants for AML. Bone Marrow Transplant 36 (2005) 525-530
24. Elmaagacli A.H., Ottinger H., Koldehoff M., Peceny R., Steckel N.K., Trenschel R., Biersack H., Grosse-Wilde H., and Beelen D.W. Reduced risk for molecular disease in patients with chronic myeloid leukemia after transplantation from a KIR-mismatched donor. Transplantation 79 (2005) 1741-1747
25. Giebel S., Locatelli F., Lamparelli T., Velardi A., Davies S., Frumento G., Maccario R., Bonetti F., Wojnar J., Martinetti M., et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102 (2003) 814-819
26. Beelen D.W., Ottinger H.D., Ferencik S., Elmaagacli A.H., Peceny R., Trenschel R., and Grosse-Wilde H. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 105 (2005) 2594-2600
27. Kroger N., Shaw B., Iacobelli S., Zabelina T., Peggs K., Shimoni A., Nagler A., Binder T., Eiermann T., Madrigal A., et al. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol 129 (2005) 631-643
28. Cook M.A., Milligan D.W., Fegan C.D., Darbyshire P.J., Mahendra P., Craddock C.F., Moss P.A., and Briggs D.C. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood 103 (2004) 1521-1526
29. Sobecks R.M., Ball E.J., Maciejewski J.P., Rybicki L.A., Brown S., Kalaycio M., Pohlman B., Andresen S., Theil K.S., Dean R., and Bolwell B.J. Survival of AML patients receiving HLA-matched sibling donor allogeneic bone marrow transplantation correlates with HLA-Cw ligand groups for killer immunoglobulin-like receptors. Bone Marrow Transplant 39 (2007) 417-424
30. La Nasa G., Littera R., Locatelli F., Giardini C., Ventrella A., Mulargia M., Vacca A., Orru N., Orru S., Piras E., et al. Status of donor-recipient HLA class I ligands and not the KIR genotype is predictive for the outcome of unrelated hematopoietic stem cell transplantation in beta-thalassemia patients. Biol Blood Marrow Transplant 13 (2007) 1358-1368
31. Savani B.N., Mielke S., Adams S., Uribe M., Rezvani K., Yong A.S., Zeilah J., Kurlander R., Srinivasan R., Childs R., et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukaemia. Leukemia 21 (2007) 2145-2152
32. Verheyden S., Schots R., Duquet W., and Demanet C. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia 19 (2005) 1446-1451
33. Kim S.Y., Choi H.B., Yoon H.Y., Choi E.J., Cho B., Kim H.K., Kim Y.J., Kim H.J., Min C.K., Kim D.W., et al. Influence of killer cell immunoglobulin-like receptor genotypes on acute graft-vs-host disease after unrelated hematopoietic stem cell transplantation in Koreans. Tissue Antigens 69 Suppl. 1 (2007) 114-117
34. McQueen K.L., Dorighi K.M., Guethlein L.A., Wong R., Sanjanwala B., and Parham P. Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. Hum Immunol 68 (2007) 309-323
35. Triplett B.M., Horwitz E.M., Iyengar R., Turner V., Holladay M.S., Gan K., Behm F.G., and Leung W. Effects of activating NK cell receptor expression and NK cell reconstitution on the outcomes of unrelated donor hematopoietic cell transplantation for hematologic malignancies. Leukemia 23 (2009) 1278-1287
36. Clausen J., Wolf D., Petzer A.L., Gunsilius E., Schumacher P., Kircher B., Gastl G., and Nachbaur D. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Clin Exp Immunol 148 (2007) 520-528